What happened to Dishman Pharma shares?
What happened to Dishman Pharma shares?
NEW DELHI: Shares of Dishman Pharmaceuticals shot up 20 per cent in Tuesday’s trade after the drugmaker informed exchanges that its amalgamation with Carbogen Amcis (India) (CAIL) and Dishman Care (DCL) has become effective from March 17.
Is it good to buy Dcal share?
Dishman Carbogen Amcis Limited (NSE: DCAL) As on 3rd Jun 2022 DCAL Share Price closed @ 119.15 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 195.22 & Strong Sell for SHORT-TERM with Stoploss of 159.13 we also expect STOCK to react on Following IMPORTANT LEVELS.
What does dishman carbogen do?
The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals vitamins & chemicals and disinfectants with presence in Switzerland UK Europe China and other countries.
What happened Dishman Pharma?
Dishman Pharmaceuticals and Chemicals announced that pursuant to merger, the Company has been merged into CAIL and subsequently, in terms of the said Scheme, the name of Transferee Company i.e. Carbogen Amcis (India) has been changed to ‘Dishman Carbogen Amcis’ (“DCAL”) w.e.f. 27 March, 2017.
Who is the owner of Dishman Pharma?
Mr. Janmejay R. Vyas
Dishman Pharmaceuticals and Chemicals
| Type | Public |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1983 |
| Headquarters | Ahmedabad, India, Gujarat, India |
| Key people | Mr. Janmejay R. Vyas, Chairman Managing Director Mr. Arpit J. Vyas, Managing Director, Global CFO Dr. Himani Dhotre, C.E.O Mr. Dieter Thueer, Global Head HR |
What are the products of Dishman carbogen?
PREMARKET
| Finished Products | ||
|---|---|---|
| PRODUCT NAME | UNITS | SALES VALUE (Rs Cr.) |
| Bulk Drugs & API | N.A | 162.7700 |
| Bulk Drugs & API | N.A | 162.7700 |
| Bulk Drugs & API | N.A | 162.7700 |
What is Dishman Carbogen Amcis Ltd?
Dishman (Dishman Carbogen Amcis Limited) is a multinational company specialized in the manufacture of active ingredients for the pharmaceutical industry. Dishman employs over 1,000 people worldwide and delivered annual net sales of around US$200m 2011.
